Submit to Special Issue Submit Abstract to Special Issue Review for Veterinary Sciences Propose a Special Issue

Journal Menu

Journal Browser

Histopathology and Therapy in Small Animals Oncology

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Veterinary Sciences (ISSN 2306-7381). This special issue belongs to the section "Veterinary Internal Medicine".

Deadline for manuscript submissions: 10 July 2024 | Viewed by 9691

Share This Special Issue

Special Issue Editors

Dr. Riccardo Finotello

E-Mail Website
Guest Editor

Head of Veterinary Oncology, Veterinary Oncology and Radiation Oncology Unit, AniCura Italy, 40126 Bologna, Italy
Interests: veterinary oncology; veterinary pathology; veterinary medicine; veterinary diagnostics; oncology; cancer biology; clinical oncology
Special Issues, Collections and Topics in MDPI journals

Dr. Guido Rocchigiani

E-Mail Website
Guest Editor

Lecturer in Veterinary Pathology, Leahurst Campus, University of Liverpool, Chester Highroad, Liverpool CH64 7TE, UK
Interests: animal pathology; forensic pathology; PCR; histology; parasitology; horse pathology; immunohistochemistry; oncology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The theme of this 2023 Special Issue of Veterinary Sciences will focus on “Histopathology and Therapy in Small Animal Oncology”. The editorial team thought that this topic was appropriate following the progress in the diagnostic pathology and clinical oncology of small animals achieved over the past decade. The interest in veterinary oncology has increased exponentially, resulting in new florid collaborations among research groups from different parts of the world, which have improved the management of common neoplastic diseases and understanding of rarer disorders. This also reflects an increased awareness of pets’ parents, who are willing to face complex diagnostic pathways and demanding treatment courses. The widespread presence of veterinary specializations has certainly greatly contributed to this scenario, continuing to raise standards and crafting routinary collaborations among specialists who serve the public, its animals, and the veterinary profession by providing high-quality services.

Advances in small animals’ oncology research also continue to benefit One Health, as pets share genetic similarities with humans but age faster; this comparative approach continues to maintain a promising role in increasing knowledge on neoplastic diseases and therapeutic options.

In this Special Issue, we invite all actors in the field of veterinary oncology, including but not restricted to veterinary pathologists, oncologists, and surgeons. We invite researchers to submit research manuscripts and reviews.

Dr. Riccardo Finotello
Dr. Guido Rocchigiani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Veterinary Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

cancer
small animals
veterinary oncology
diagnostic pathology
immunohistochemistry
molecular biology
chemotherapy
electrochemotherapy
biomarkers
canine
feline

Published Papers (4 papers)

Download All Papers

Research

Jump to: Other

12 pages, 889 KiB

Open AccessArticle

Meloxicam in Combination with Mitoxantrone or Vinblastine as First-Line Treatment for Non-Resectable Urothelial Cell Carcinoma in Dogs

by Estel.la Ciriano Cerdà, Alenka Lavra Zajc, Riccardo Finotello, Kirsty Macdonald, Filipa Lyseight, Nele Van Den Steen, Katia Sanchez Gonzalez, Mary Marrington and Jessica Grant

Vet. Sci. 2023, 10(8), 529; https://doi.org/10.3390/vetsci10080529 - 21 Aug 2023

Viewed by 2651

Abstract

Cyclooxygenase (COX) inhibitors have been demonstrated to have antitumour activity in canine urothelial cell carcinoma (UCC), given as a sole treatment or in combination with chemotherapy. The purpose of this retrospective multi-institutional study was to assess the efficacy of meloxicam in combination with mitoxantrone or vinblastine as a first-line treatment for non-resectable canine UCC. Gastrointestinal adverse effects (AEs) of these treatment combinations were also assessed. A total of 28 dogs met the inclusion criteria, 21/28 dogs received mitoxantrone and meloxicam, and 7/28 received vinblastine and meloxicam. Tumour response (TR) and AE were evaluated according to Veterinary Co-Operative Oncology Group (VCOG) criteria. The endpoint of the study was the time to tumour progression (TTP). The mitoxantrone-group induced 24% partial response and 62% stable disease, while the vinblastine-group induced 14% and 86%, respectively. Median TTP was 84 days (mitoxantrone and meloxicam, 70 days; and vinblastine and meloxicam, 178 days). The presence of metastatic disease significantly decreased TTP (p = 0.007). Gastrointestinal AEs were reported in 21.4% of the patients, with the most common being VCOG grade 1–2 diarrhoea. Meloxicam is a well-tolerated NSAID when combined with mitoxantrone or vinblastine as first-line treatment for non-resectable canine UCC. Full article

(This article belongs to the Special Issue Histopathology and Therapy in Small Animals Oncology)

► Show Figures

Figure 1

17 pages, 1391 KiB

Open AccessArticle

The Prognostic Role of Preoperative Hematological and Inflammatory Indices in Canine Appendicular Osteosarcoma

by Konstantinos Rigas, Jean-Benoit Tanis, Emanuela Morello, Gerry Polton, Laura Marconato, Marlon Carroll, EstelLa Ciriano Cerda, Sofia Ramos, Charlotte Baker and Riccardo Finotello

Vet. Sci. 2023, 10(8), 495; https://doi.org/10.3390/vetsci10080495 - 01 Aug 2023

Viewed by 1521

Abstract

Hematological indices play a prognostic role in human osteosarcoma (OSA), but data are limited in dogs. The aim of this retrospective multicentric cohort study was to investigate the prognostic significance of pre-operative hematological/inflammatory indices in a cohort of client-owned dogs with appendicular OSA receiving standardized treatment. Cut-offs associated with progression-free survival (PFS) for pre-operative hematological values/ratios were established using the minimal p-value approach. Historical prognostic factors were also assessed. Statistical analyses were performed for the whole population and after the exclusion of sighthounds. Fifty-nine dogs were included (13 were sighthounds). Multivariable analysis revealed that a low neutrophil count (<4.37 × 10⁹/L, HR0.28, CI 95% 0.13–0.61, p = 0.001), a high red blood cell count (≥7.91, HR3.5, CI 95% 1.56–7.9, p = 0.002), and a proximal humerus location (HR3.0, CI 95% 1.48–6.1, p = 0.002) were associated with shorter PFS. In the sighthound-only population, only OSA location was significantly associated with PFS in univariable analysis. When sighthounds were excluded, a low neutrophil count, a low monocyte count, and a proximal humerus location were associated with shorter PFS, in multivariable analysis. Neutrophil count and possibly monocyte and red blood cell counts can be useful prognostic markers in canine OSA treated with amputation and adjuvant carboplatin. However, not all indices are appropriate in sighthounds. Full article

(This article belongs to the Special Issue Histopathology and Therapy in Small Animals Oncology)

► Show Figures

Figure 1

Other

Jump to: Research

7 pages, 2348 KiB

Open AccessCase Report

B-Cell Lymphoma of the Middle Ear Treated with Multidrug Chemotherapy in a Cat

by Tomoko Takahashi, Hiroyuki Nagata and Hirotaka Kondo

Vet. Sci. 2023, 10(9), 585; https://doi.org/10.3390/vetsci10090585 - 21 Sep 2023

Viewed by 1572

Abstract

Primary lymphoma of the middle ear is rare in cats, and little information has been accumulated on the treatment and course. An 11-year-old spayed female mixed-breed cat was brought to our hospital with facial nerve paralysis, which had been stable using prednisolone for 3 months. She was diagnosed with B-cell lymphoma of the right middle ear after otoscopic sampling, which showed evidence of the filling of bilateral tympanic bullae on computed tomography. Hepatic involvement was suspected, and she was treated with multidrug chemotherapy, resulting in clinical remission. On day 176, magnetic resonance imaging and computed tomography were performed at checkup, revealing tumor invasion into the nasopharyngeal region and the recurrence of hepatic lesions without any brain abnormality. Nasal congestion then worsened, and the patient died on day 228 after presenting with generalized seizures. Clinicians should be mindful of middle ear lymphoma as a differential diagnosis in cats who present with a sign of otitis media, especially whose condition does respond to corticosteroid treatment. The prognosis for feline middle ear lymphoma might not be as poor as previous reports, and multidrug chemotherapy might result in remission of the disease. Full article

(This article belongs to the Special Issue Histopathology and Therapy in Small Animals Oncology)

► Show Figures

Figure 1

11 pages, 1731 KiB

Open AccessCase Report

Successful Treatment of Central Nervous System Lymphoma with Combination Therapy of Nimustine and Prednisolone in Two Dogs

by Yuko Mizutani, Yoshiyuki Inoue, Yoshimichi Goda, Shinya Mizutani, Taketoshi Asanuma, Naoki Miura, Yuichi Hidaka, Reiichiro Sato and Hiroyuki Satoh

Vet. Sci. 2023, 10(9), 533; https://doi.org/10.3390/vetsci10090533 - 22 Aug 2023

Viewed by 2865

Abstract

Of intracranial tumors, primary central nervous system lymphoma (PCNSL) is rare in dogs. Herein, we describe our experience with two dogs (a 3-year-old intact female toy poodle and a 5-year-old spayed female toy poodle) that developed neurological symptoms. Magnetic resonance imaging (MRI) revealed intracranial disseminated lesions. Cerebrospinal fluid (CSF) examination revealed pleocytosis and B-cell monoclonal proliferation in both cases. PCNSL or secondary central nervous system lymphoma (SCNSL) was diagnosed on the basis of MRI findings and CSF examinations. Nimustine (ACNU) is a nitrosourea alkylating agent, a class of drugs that includes lomustine. Nimustine is mainly used to treat human intracranial neoplasia because of its high permeability across the blood-brain barrier. The dogs in this study were treated with combined chemotherapy comprising nimustine and prednisolone, which achieved complete or nearly complete remission of neurological symptoms and long-term survival (>2583 days and 1218 days), but with problematic adverse effects. We determined that the dose of nimustine for canine PCNSL or SCNSL with intravenous infusion was 25–30 mg/m² every 3–4 weeks for a total of four times; however, the data were insufficient to determine the optimal regimen. Full article

(This article belongs to the Special Issue Histopathology and Therapy in Small Animals Oncology)

► Show Figures